Healthcare Business Review: Gilead Faces HEPATITIS Fears, Repros Gets FDA MEETING
Here are Monday’s top stories:
Biotech firms such as Gilead Sciences, Inc. (NASDAQ:GILD), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), and Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), which are among firms specializing in the field of active hepatitis, were testing for more than 3,000 persons who might have been infected with hepatitis C. The trial was cancelled after the system became overwhelmed. Fears are increasing following the indictment of a former lab technician at a New Hampshire hospital last week for allegedly infecting 31 individuals with the virus.
Repros Therapeutics Inc. (NASDAQ:RPRX) reports that the FDA has set a meeting to discuss the Phase 2 tests for its low dose oral Proellex treatment for endometriosis. The talks will be in the form of a teleconference and held during the last week of August.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.